Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from...
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers.
Target Price
The average target price of PHVS is 50 and suggests 80% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell